Two retrospective studies have reported female sex, overweight, initial biliary stent insertion, platelet count ≤ 15 × 104/L, and heterozygosity for either the UGT1A1*28 or UGT1A1*6 alleles as risk factors for FN in PC patients receiving FOLFIRINOX [10,11]. Here, UGT1A1 is linked to pachyonychia congenita.